Phase I study of the safety, tolerability, and pharmacokinetics of oral CP-868,596, a highly specific platelet-derived growth factor receptor tyrosine kinase inhibitor in patients with advanced cancers.
| Autor: | Lewis NL, Lewis LD, Eder JP, Reddy NJ, Guo F, Pierce KJ, Olszanski AJ, Cohen RB, Lewis, Nancy L, Lewis, Lionel D, Eder, Joseph P, Reddy, Nandi J, Guo, Feng, Pierce, Kristen J, Olszanski, Anthony J, Cohen, Roger B |
|---|---|
| Zdroj: | Journal of Clinical Oncology; 11/1/2009, Vol. 27 Issue 31, p5262-5269, 8p |
| Databáze: | Supplemental Index |
| Externí odkaz: |
|